Targeting RAS and PI3K in lung cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS not only drives the RAF/MAPK/ERK pathway but also directly activates PI3K to promote the PI3K/AKT/mTOR signaling [107].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [107]
In the citing paper
“Combing ARS-1620 with PI3K/AKT/mTOR pathway inhibitors could overcome resistance to ARS-1620 in both in vitro and in vivo models, including patient-derived xenograft models [110].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [110]
In the citing paper
“Analysis of a panel of KRAS G12C NSCLC cell lines treated with ARS-1620 revealed that variations of cellular response to KRAS G12C inhibition are associated with the suppression of MEK/ERK and PI3K/AKT signaling [110].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [110]
Citations
Cites
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Self-citationTargeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Lim, K.-H., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 159
Cited by
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
“pathways activated by EGFR have also received great attention as potential targets for the development of new therapeutic drugs for lung cancer [165,166].”
BackgroundTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
“HCC 3 (5) — — — — — — — — 1 (33) 2 (67)”
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
Shi, Q., Qin, L., Wei, W., Geng, F., Fan, R., Shik Shin, Y., Guo, D., Hood, L., Mischel, P. S., & Heath, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110865109 · Cited by 318
“This preferential activation of MAPK signaling pathways in response to EGF activation in GBM cells containing PTEN was validated by immunoblot analysis (Fig.”
BackgroundInfluential
Metadata
- Authors
- Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Corresponding author
- Downward, Julian
- ORCID
- Downward, Julian
- Venue
- Nature Medicine
- Published
- 2008-12
- Volume
- 14
- Issue
- 12
- Pages
- 1315-1316
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1999354555
- Cited by
- 80
- References
- 9
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 4 · 2013: 4 · 2012: 4
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ras, phosphatidylinositol 3-kinase, lung cancer, PI3K inhibitors, MAPK kinase inhibitors, combination therapy, tumor growth inhibition
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Enzyme Inhibitors, Humans, Lung Neoplasms, ras Proteins, Phosphatidylinositol 3-Kinases, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.